UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 10, 2015

 

PHARMATHENE, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware 001-32587 20-2726770
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

  

One Park Place, Suite 450
Annapolis, Maryland
  21401
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (410) 269-2600

 

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

At the annual meeting of stockholders (the “Annual Meeting”) of PharmAthene, Inc. (the “Company”) held on June 10, 2015, the holders of the Company’s common stock voted to elect each of the following directors to serve until the next annual meeting and until his successor is duly elected and qualified:

 

Director   Votes For   Votes Withheld   Broker Non-Votes
John M. Gill   21,454,525   388,735   28,193,872
Eric I. Richman   21,439,347   403,913   28,193,872
Jeffrey W. Runge, M.D.   21,458,525   384,735   28,193,872
Mitchel B. Sayare, Ph.D.   21,459,372   383,888   28,193,872
Derace L. Schaffer, M.D.   21,469,425   373,835   28,193,872
Steven St. Peter, M.D.   21,469,372   373,888   28,193,872

 

At the Annual Meeting, the Company’s stockholders also voted on the following proposals:

 

Proposal   For   Against   Abstain   Broker Non-Votes
To consider and provide an advisory (non-binding) vote to approve the compensation of the Company’s named executive officers as described in the proxy statement   21,079,546   636,066   127,648   28,193,872
To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015   48,732,662   1,192,953   111,517   N/A

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

     
 

PHARMATHENE, INC.

 

     
Date:  June 12, 2015 By:   /s/ Philip MacNeill
 

Philip MacNeill

Vice President, Chief Financial Officer, Treasurer and
Secretary